Alterity Therapeutics Ltd. (AU:ATH) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alterity Therapeutics has unveiled promising data from its bioMUSE study at an international symposium, showcasing advanced imaging techniques that track brain volume changes in Multiple System Atrophy (MSA) patients. These findings, which introduce the MSA Atrophy Index as a potential biomarker, could significantly enhance the evaluation of disease-modifying therapies in MSA. This breakthrough offers hope for better understanding and managing this debilitating neurodegenerative disorder.
For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.